What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

Ethical Concerns of CRISPR: A Comprehensive Overview

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Introduction to CRISPR and Its Ethical Dimensions

What is CRISPR-Cas9?

CRISPR-Cas9 is a naturally occurring adaptive immune system found in bacteria and archaea, repurposed as a programmable genome-editing tool. The acronym stands for Clustered Regularly Interspaced Short Palindromic Repeats, and Cas9 is the CRISPR-associated protein 9, an RNA-guided endonuclease. The system functions through a guide RNA (gRNA) that contains a 20-nucleotide sequence complementary to a target DNA region, directing the Cas9 enzyme to create a double-strand break (DSB) at that precise locus. The cell then repairs the break primarily through one of two pathways: non-homologous end joining (NHEJ), which is error-prone and frequently introduces insertions or deletions (indels) that disrupt gene function, or homology-directed repair (HDR), which uses a donor template to introduce specific sequence changes. This mechanism is described in greater detail in our CRISPR Explained resource.

The revolutionary aspect of CRISPR-Cas9 lies in its simplicity, efficiency, and versatility compared to earlier genome-editing technologies such as zinc-finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs). A researcher can design a new gRNA in days, and the system works across virtually all organisms, from bacteria to plants to mammals. This accessibility has democratized genetic engineering, but it has also accelerated the urgency of addressing the ethical dimensions of genome modification.

Why CRISPR Raises Ethical Questions

CRISPR technology presents a paradox: it offers unprecedented potential to treat genetic diseases, improve crop resilience, and advance fundamental biological research, yet it simultaneously raises profound ethical questions about the limits of human intervention in the genome. The core ethical concerns cluster around several themes: the distinction between somatic and germline editing, the risk of unintended off-target mutations, the challenge of obtaining meaningful informed consent, the potential to exacerbate social inequalities, the adequacy of existing regulatory frameworks, and the ecological consequences of releasing edited organisms into the environment. These concerns are not merely hypothetical; they have been brought into sharp focus by real-world applications, including the first gene-edited babies born in 2018. Understanding these ethical issues requires both a technical grasp of the underlying biology and a structured approach to moral reasoning, which we will develop throughout this article. For a broader treatment of these themes, see CRISPR Ethical Considerations.

Germline Editing and Heritable Changes

Somatic vs. Germline Editing

The distinction between somatic and germline editing is foundational to any ethical analysis of CRISPR. Somatic editing targets non-reproductive cells—such as hepatocytes, T lymphocytes, or muscle cells—and the introduced changes are confined to the treated individual. These modifications are not passed to offspring. An example is the ex vivo editing of autologous CD34+ hematopoietic stem cells to reactivate fetal hemoglobin expression in patients with β-thalassemia or sickle cell disease, an approach that has shown clinical promise.

Germline editing, by contrast, targets gametes (sperm or eggs) or early embryos, and the resulting genetic changes are heritable, meaning they will be transmitted to all subsequent generations. This distinction is not merely technical; it carries profound ethical weight. Somatic editing is often analogized to conventional medical treatment—it affects only the patient, and its risks and benefits can be weighed in the context of individual consent. Germline editing, however, introduces changes into the human gene pool, affecting individuals who have no voice in the decision and whose genetic makeup will be permanently altered.

The ethical debate over germline editing centers on several concerns: the uncertainty of long-term effects across generations, the potential for unintended consequences that cannot be reversed, and the question of whether humanity has the moral authority to make irreversible decisions about the genetic inheritance of future persons. Some ethicists argue that germline editing could be permissible if it is used to eliminate devastating monogenic diseases such as Huntington's disease, which is caused by a dominant mutation in the HTT gene. Others contend that the risks are too great and the benefits too uncertain to justify any germline modification at present. The Ethical Issues of CRISPR page provides additional context on this ongoing debate.

The Case of the First Gene-Edited Babies

The ethical concerns surrounding germline editing moved from theoretical debate to concrete reality in November 2018, when He Jiankui, a Chinese biophysicist, announced that he had used CRISPR-Cas9 to edit the CCR5 gene in twin embryos, which were then implanted and resulted in live births. The stated aim was to confer resistance to HIV-1 infection, as CCR5 encodes a co-receptor that the virus uses to enter CD4+ T cells. The editing targeted the CCR5 gene in embryos at the single-cell stage, and the resulting babies—known as Lulu and Nana—were reported to have mosaic genomes, meaning that not all cells carried the intended modification.

This event triggered widespread condemnation from the scientific community for multiple reasons. First, the experiment bypassed established ethical and regulatory norms; no independent ethics committee had approved the work, and the consent process was opaque. Second, the scientific justification was weak—CCR5-Δ32 homozygotes are naturally resistant to HIV, but safe and effective alternatives exist, including pre-exposure prophylaxis (PrEP) and assisted reproductive technologies that avoid HIV transmission. Third, the off-target effects of the editing were not adequately assessed, and the long-term health consequences for the children remain unknown. Fourth, the experiment was conducted in a context where the regulatory framework was ambiguous, highlighting the dangers of "science by stealth" in jurisdictions with weak oversight.

The case illustrates the central ethical problem of germline editing: the decision to modify the human germline was made by a single individual, without meaningful consent from the affected individuals (the future children) or from society at large. It also demonstrates the difficulty of containing the technology once it becomes accessible. The scientific community's response—calls for a moratorium on clinical germline editing and the development of international governance frameworks—reflects the recognition that the technology has outpaced our ethical and regulatory infrastructure.

Off-Target Effects and Unintended Consequences

Mechanisms of Off-Target Effects

Off-target effects are unintended edits at genomic sites that share sequence similarity with the intended target. The Cas9 enzyme relies on a 20-nucleotide guide sequence, but it can tolerate mismatches, particularly in the PAM-proximal region (the protospacer adjacent motif, a 5'-NGG sequence required for Cas9 binding). Mismatches in the 5' end of the guide RNA are more readily tolerated than those in the 3' end, which is known as the "seed region" (approximately 8–12 nucleotides adjacent to the PAM). As a result, Cas9 can cleave at sites with up to 3–5 mismatches, depending on the specific guide and the local chromatin context.

The frequency of off-target events varies widely depending on the guide RNA sequence, the cell type, the delivery method, and the duration of Cas9 expression. High-fidelity variants of Cas9, such as SpCas9-HF1 and eSpCas9(1.1), have been engineered to reduce off-target activity by weakening the interaction between the enzyme and the non-target DNA strand. Additionally, the use of truncated guide RNAs (17–18 nucleotides) or paired nickases (where two Cas9 nickase mutants create staggered single-strand breaks) can reduce off-target editing. Nevertheless, no current method eliminates off-target effects entirely.

The ethical significance of off-target effects lies in the principle of non-maleficence—the duty to avoid causing harm. In a somatic gene therapy context, an off-target mutation in a tumor suppressor gene such as TP53 could theoretically increase cancer risk. In a germline context, off-target mutations would be inherited by all future generations, amplifying the potential harm. The challenge is that detecting off-target effects is inherently difficult, as discussed below.

Detection Methods and Limitations

Several methods exist to identify off-target mutations, each with distinct limitations. Whole-genome sequencing (WGS) is the most comprehensive approach, but it is expensive and requires high sequencing depth to detect low-frequency variants. Targeted amplicon sequencing can detect edits at predicted off-target sites, but it only examines sites that are computationally predicted, potentially missing unexpected events. Biochemical methods such as Digenome-seq, CIRCLE-seq, and GUIDE-seq (genome-wide unbiased identification of double-strand breaks evaluated by sequencing) use in vitro or cell-based approaches to identify Cas9 cleavage sites genome-wide. GUIDE-seq, for example, uses a double-stranded oligodeoxynucleotide tag that is incorporated into DSBs, allowing their identification by sequencing.

Despite these tools, the detection of off-target effects remains incomplete. The sensitivity of detection depends on the cell population analyzed; a mutation present in a small fraction of cells may be missed by bulk sequencing. Furthermore, the functional consequences of off-target mutations are often unknown—a mutation in a non-coding region may have no phenotypic effect, while a mutation in a regulatory element could have subtle but significant consequences. The ethical duty to minimize harm therefore requires not only the use of high-fidelity Cas9 variants and careful guide design but also a realistic acknowledgment that our detection methods are imperfect. This uncertainty is a key argument for caution, particularly in germline applications where errors are irreversible. For a deeper dive into the technical aspects of CRISPR editing, see CRISPR Knockout and CRISPR Knock.

Informed Consent and Autonomy

Consent in Somatic Gene Therapy

In somatic gene therapy, the ethical framework for informed consent is relatively well established, drawing on principles from clinical research and medical ethics. The patient (or their legal guardian) must be informed of the potential benefits, risks, and alternatives, and must voluntarily agree to the procedure. For example, in the context of CAR-T cell therapy for B-cell malignancies, where a patient's T cells are harvested, genetically modified to express a chimeric antigen receptor, and re-infused, the consent process must explain the risk of cytokine release syndrome, neurotoxicity, and the possibility of treatment failure.

However, somatic gene therapy introduces unique consent challenges. The long-term effects of gene editing are often unknown, particularly for novel therapies. Patients may be in a vulnerable state—gravely ill, with limited treatment options—which can compromise the voluntariness of their consent. Additionally, the complexity of the technology may make it difficult for patients to fully understand what they are consenting to. The ethical obligation is to ensure that consent is truly informed, which requires clear communication and, ideally, the involvement of genetic counselors or patient advocates.

Consent in Germline Editing

Germline editing presents a fundamentally different consent problem: the individuals whose genomes are modified—the resulting children and all their descendants—cannot consent to the procedure. This is a violation of the principle of respect for autonomy, which holds that individuals have the right to make decisions about their own bodies and genetic makeup. Proponents of germline editing argue that this objection is not decisive, because we routinely make decisions that affect future people without their consent, such as environmental policies or public health measures. However, these decisions are typically made through democratic processes and can be revised; germline editing is irreversible and made by a small number of individuals.

A related concern is the "right to an open future," a concept articulated by philosopher Joel Feinberg. This principle holds that children have a right to a future in which their options are not unjustly foreclosed. Germline editing could be seen as violating this right if it imposes a particular genetic makeup on a child without their input. Conversely, one could argue that editing out a devastating disease gene expands the child's future options by giving them a healthier life. The ethical challenge is distinguishing between interventions that are clearly therapeutic (e.g., correcting a mutation that causes Tay-Sachs disease) and those that are enhancement-oriented (e.g., increasing height or cognitive ability), where the ethical justification is far more contested.

The difficulty of obtaining meaningful consent for germline editing is a central reason why many bioethicists argue for a moratorium on clinical applications until the technology is better understood and a robust governance framework is in place. The CRISPR Ethical Implications page explores these issues in further detail.

Equity, Access, and Social Justice

Cost and Availability

The development of CRISPR-based therapies is expensive. The research and development costs, the manufacturing of viral vectors or lipid nanoparticles for delivery, the need for specialized clinical infrastructure, and the regulatory approval process all contribute to high prices. For example, the first gene therapies approved in the United States and Europe have been priced in the hundreds of thousands to millions of dollars per patient. Casgevy (exagamglogene autotemcel), a CRISPR-based therapy for sickle cell disease and β-thalassemia approved in 2023, was priced at $2.2 million in the United States.

This pricing creates a stark equity problem: if CRISPR therapies are only accessible to the wealthy or to citizens of high-income countries, they will exacerbate existing health disparities. Sickle cell disease, for instance, disproportionately affects people of African descent, including populations in low- and middle-income countries where access to advanced medical care is limited. If a curative therapy is available only in Boston or London, the global burden of the disease will remain largely unaddressed.

The ethical obligation to ensure fair distribution of CRISPR technologies rests on several principles. The principle of justice requires that the benefits and burdens of research and technology be distributed fairly. The principle of solidarity suggests that we have a collective responsibility to ensure that life-saving technologies are available to all who need them, regardless of ability to pay. Achieving this will require innovative pricing models, technology transfer agreements, and investment in healthcare infrastructure in underserved regions.

Global Disparities in CRISPR Research

The inequities in CRISPR are not limited to clinical applications; they also extend to research capacity. High-income countries, particularly the United States, China, and European nations, dominate CRISPR research, both in terms of funding and in terms of the number of publications and patents. Low- and middle-income countries often lack the infrastructure, trained personnel, and funding to conduct cutting-edge genome-editing research. This disparity has several ethical implications.

First, it means that the research agenda is set by wealthy nations, which may not prioritize diseases that predominantly affect poorer populations. For example, CRISPR research on neglected tropical diseases is far less common than research on cancers or genetic disorders prevalent in high-income countries. Second, it raises concerns about "helicopter research," where scientists from wealthy countries conduct research in poorer countries without building local capacity or ensuring that the benefits accrue to the local population. Third, it creates a risk of "ethics dumping," where researchers from countries with strong ethical oversight conduct studies in countries with weaker regulations, as occurred in the He Jiankui case.

Addressing these disparities requires a commitment to capacity building, open-access publishing, and the development of international research partnerships that are genuinely collaborative. It also requires a recognition that the ethical issues of CRISPR are not confined to the technology itself but are embedded in broader structures of global inequality.

Regulatory and Governance Challenges

National Regulations

The regulatory landscape for CRISPR varies widely across countries, reflecting different cultural, political, and legal traditions. In the United States, the Food and Drug Administration (FDA) regulates gene-editing products as biological products or drugs, and clinical trials require Investigational New Drug (IND) applications. Somatic gene therapies have been approved, but the FDA has stated that it will not review applications for germline editing, effectively prohibiting it. In the European Union, gene-edited organisms are regulated under the Genetically Modified Organisms (GMO) Directive, which imposes strict requirements for risk assessment and labeling. However, a 2018 ruling by the Court of Justice of the European Union clarified that organisms edited by techniques such as CRISPR are subject to the same regulations as traditional GMOs, a decision that has been criticized by some scientists as overly restrictive.

In China, the regulatory framework has been less clear. While the National Health Commission has issued guidelines requiring ethical review for gene-editing research, the enforcement has been inconsistent, as the He Jiankui case demonstrated. In the United Kingdom, the Human Fertilisation and Embryology Authority (HFEA) regulates the use of embryos in research, and the country has established a framework for mitochondrial replacement therapy, which involves germline modification, but it has not approved heritable genome editing for clinical use.

The patchwork of national regulations creates several problems. It allows "regulatory arbitrage," where researchers or companies can move their work to countries with weaker oversight. It also creates uncertainty for researchers and companies operating internationally, as they must navigate conflicting legal requirements. The ethical need for oversight is clear, but the question of what form that oversight should take—and at what level (national, regional, or international)—remains unresolved.

International Guidelines and Treaties

Several international bodies have addressed the governance of genome editing. The World Health Organization (WHO) established an Expert Advisory Committee on Developing Global Standards for Governance and Oversight of Human Genome Editing, which published recommendations in 2021. These recommendations call for a governance framework that includes transparency, accountability, and the involvement of diverse stakeholders, including patients, ethicists, and the public. The WHO also established a registry for human genome editing research to promote transparency.

The Council of Europe's Convention on Human Rights and Biomedicine (Oviedo Convention) prohibits germline modification in its Article 13, but this convention has only been ratified by a subset of European countries. The International Commission on the Clinical Use of Human Germline Genome Editing, convened by the U.S. National Academy of Medicine and the Royal Society, published a report in 2020 that outlined criteria for the responsible clinical use of germline editing, but it stopped short of endorsing such use, citing the need for further research and public debate.

Despite these efforts, there is no binding international treaty that prohibits or regulates germline editing. The United Nations has not reached consensus on the issue, and the existing guidelines are largely advisory. This governance gap is ethically problematic because it leaves decisions about a technology with profound implications for human evolution to individual nations or even individual researchers. The development of a binding international instrument, such as a treaty under the auspices of the WHO or UNESCO, is a pressing ethical priority.

Environmental and Agricultural Ethics

Gene Drives and Ecosystem Disruption

CRISPR has enabled the development of gene drives, genetic systems that bias inheritance so that a particular trait is transmitted to a disproportionately high percentage of offspring. In a normal Mendelian inheritance, a gene has a 50% chance of being passed on; a gene drive can increase this to 90% or higher. This is achieved by inserting a CRISPR-Cas9 cassette into a specific locus, which then cuts the homologous chromosome in a heterozygote, causing the cell to repair the break using the drive-containing chromosome as a template, thereby converting the heterozygote into a homozygote.

Gene drives have been proposed for applications such as eliminating malaria by spreading a sterility trait through mosquito populations (e.g., Anopheles gambiae), or eradicating invasive species from islands. However, they raise profound ethical and ecological concerns. A gene drive released into a wild population could spread rapidly and potentially across national borders, with effects that are difficult to predict or reverse. The extinction of a species, even a disease vector, could have cascading effects on ecosystems. The precautionary principle—which holds that in the face of potential irreversible harm, lack of full scientific certainty should not be used as a reason to postpone action—suggests that gene drives should be approached with extreme caution.

The ethical framework for gene drives requires a risk assessment that considers not only the intended effects but also the potential for unintended ecological consequences. It also requires engagement with local communities and indigenous peoples who may be affected by the release of gene-drive organisms. The Cartagena Protocol on Biosafety, an international agreement under the Convention on Biological Diversity, provides a framework for the transboundary movement of living modified organisms, but it does not specifically address gene drives.

Labeling and Consumer Choice

The use of CRISPR in agriculture raises ethical questions about consumer information and choice. CRISPR has been used to develop crops with improved traits, such as high-oleic-acid soybeans, non-browning mushrooms, and disease-resistant wheat. Unlike traditional GMOs, which typically involve the insertion of foreign DNA, CRISPR edits are often indistinguishable from naturally occurring mutations. This has led to debates about whether CRISPR-edited foods should be labeled as GMOs.

In the United States, the National Bioengineered Food Disclosure Standard requires labeling of foods that contain genetic material that has been modified through certain techniques, but it exempts some CRISPR-edited products if they do not contain foreign DNA. In the European Union, the 2018 Court of Justice ruling subjected CRISPR-edited organisms to the same labeling requirements as traditional GMOs. Proponents of labeling argue that consumers have a right to know how their food was produced, and that labeling allows individuals to make choices consistent with their values. Opponents argue that labeling is unnecessary and could stigmatize safe and beneficial technologies, and that it imposes additional costs on producers and consumers.

The ethical issue here is not whether CRISPR-edited foods are safe—the scientific consensus is that they are generally as safe as conventionally bred crops—but rather the balance between consumer autonomy and the promotion of beneficial technologies. A reasonable ethical framework would require transparent labeling that is accurate and not misleading, while also ensuring that the regulatory burden does not disproportionately disadvantage small-scale farmers or researchers in developing countries.

Common Pitfalls in Ethical Analysis

Avoiding Slippery Slope Fallacies

A common error in ethical analysis of CRISPR is the use of the slippery slope argument, which asserts that allowing one application will inevitably lead to more problematic applications. For example, one might argue that allowing germline editing to eliminate a fatal disease will inevitably lead to the creation of "designer babies" with enhanced intelligence or athletic ability. While it is true that the line between therapy and enhancement is blurry, the slippery slope argument is a logical fallacy if it assumes that no intermediate safeguards can be established.

A more rigorous approach is to evaluate each application on its own merits, considering the specific risks, benefits, and ethical implications. This requires distinguishing between different types of edits (e.g., somatic vs. germline, therapeutic vs. enhancement) and different contexts (e.g., clinical vs. agricultural). It also requires recognizing that the ethical permissibility of an application can change over time as more data become available and as societal values evolve.

Balancing Benefits and Risks

Another common pitfall is the failure to conduct a balanced risk-benefit analysis. Some proponents of CRISPR emphasize the potential benefits—curing genetic diseases, improving food security—while downplaying the risks. Some opponents emphasize the risks—off-target effects, ecological disruption—while downplaying the benefits. A balanced analysis requires a systematic assessment of both.

One useful framework is the principle of proportionality, which holds that the risks of an intervention must be proportionate to the expected benefits. For a life-threatening disease with no effective treatment, a higher level of risk may be acceptable. For a cosmetic or enhancement application, the risk tolerance should be much lower. This framework also requires consideration of alternatives: if a safe and effective alternative exists (e.g., preimplantation genetic diagnosis to select embryos without a disease-causing mutation), the ethical justification for germline editing is weakened.

A third pitfall is the conflation of technical and ethical issues. For example, the question "Can CRISPR cause off-target mutations?" is a technical question that can be answered empirically. The question "Is it ethical to use CRISPR in humans?" is an ethical question that requires moral reasoning. Confusing these two types of questions can lead to the erroneous conclusion that if a technology is safe, it is therefore ethical, or vice versa. A rigorous ethical analysis must separate factual questions from normative ones and address each appropriately.

Frequently Asked Questions

What are the main ethical concerns of CRISPR?

The main ethical concerns of CRISPR include germline editing and heritable changes, off-target effects and unintended consequences, challenges of informed consent and autonomy, equity and access to therapies, regulatory and governance gaps, and environmental impacts of gene drives and agricultural applications. These concerns span clinical, social, and ecological domains.

Is CRISPR ethical to use in humans?

CRISPR is ethical to use in humans under certain conditions, primarily for somatic gene therapy in the context of serious diseases where the potential benefits outweigh the risks and where informed consent is obtained. Germline editing is far more ethically problematic due to the inability to obtain consent from future generations, the risk of off-target effects, and the irreversible nature of the changes. Most international bodies currently recommend against clinical germline editing.

What is the difference between somatic and germline editing?

Somatic editing targets non-reproductive cells, and the changes are confined to the treated individual. Germline editing targets gametes or embryos, and the changes are heritable, affecting all future generations. Somatic editing is analogous to conventional medical treatment, while germline editing raises unique ethical concerns about consent, irreversibility, and the human gene pool.

Can CRISPR cause off-target mutations?

Yes, CRISPR-Cas9 can cause off-target mutations at sites that share sequence similarity with the intended target. The frequency depends on the guide RNA sequence, the Cas9 variant, and the cell type. High-fidelity Cas9 variants and careful guide design can reduce off-target effects, but they cannot eliminate them entirely. Detection methods such as GUIDE-seq and whole-genome sequencing are used to identify off-target events, but they have limitations in sensitivity.

Why is informed consent difficult for germline editing?

Informed consent is difficult for germline editing because the individuals whose genomes are modified—the resulting children and all future descendants—cannot consent to the procedure. This violates the principle of respect for autonomy. Additionally, the long-term risks of germline editing are unknown, making it difficult for anyone to provide fully informed consent.

How could CRISPR worsen social inequality?

CRISPR-based therapies are expensive, and if access is limited to the wealthy or to citizens of high-income countries, they will exacerbate existing health disparities. Diseases such as sickle cell disease disproportionately affect populations in low- and middle-income countries, where access to advanced medical care is limited. Global disparities in research capacity also mean that the benefits of CRISPR may not reach those who need them most.

What are the ethical issues with using CRISPR in agriculture?

Ethical issues in agriculture include the potential ecological impacts of gene drives, which could spread through wild populations and disrupt ecosystems; the question of whether CRISPR-edited foods should be labeled, which affects consumer choice; and concerns about the concentration of power in the hands of a few large agribusiness corporations. There are also questions about the impact on small-scale farmers and biodiversity.

Key Takeaways

CRISPR-Cas9 is a powerful and accessible genome-editing tool, but its use raises ethical concerns that must be addressed through careful analysis and governance.
The distinction between somatic and germline editing is central: somatic editing affects only the individual, while germline editing produces heritable changes with implications for future generations.
Off-target effects are a real risk, and while detection methods exist, they are imperfect; this uncertainty argues for caution, particularly in germline applications.
Informed consent is problematic for germline editing because future generations cannot consent, and the long-term risks are unknown.
CRISPR could exacerbate social inequalities if access to therapies is limited to the wealthy or to high-income countries; equitable distribution is an ethical obligation.
The regulatory landscape for CRISPR is fragmented, with no binding international treaty; robust governance frameworks are needed to prevent misuse and ensure responsible development.
Environmental applications, such as gene drives, require careful risk assessment and engagement with affected communities, guided by the precautionary principle.
Ethical analysis of CRISPR must avoid slippery slope fallacies and conduct balanced risk-benefit assessments, separating technical questions from normative ones.